Dr. Hope Rugo Examines Angiogenesis Inhibition for Advanced Breast Cancer

Dr. Rugo on Anti-Angiogenesis Therapy Response PredictorsПодробнее

Dr. Rugo on Proliferation as an Anti-Angiogenesis MarkerПодробнее

Dr. Rugo on the Efficacy of Bevacizumab in Breast CancerПодробнее

Dr. Hope Rugo – ESMO 2022 – Exploring the latest trial data & advances in breast cancer treatmentsПодробнее

Dr. Rugo on Guidelines for the Treatment of Metastatic Breast CancerПодробнее

Breast Cancer: The Next Wave By Dr. Hope RugoПодробнее

Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast CancerПодробнее

Dr. Rugo Discusses the Future of Angiogenesis in Breast CancerПодробнее

Dr. Hope Rugo on the First-line Superiority of Paclitaxel for Advanced Breast CancerПодробнее

Dr. Rugo on VEGF-A as an Avastin Response PredictorПодробнее

Dr. Rugo on Hormone Therapy for Patients With Breast CancerПодробнее

Dr. Hope Rugo | San Antonio Breast Cancer Symposium 2022 | General SessionПодробнее

Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impactsПодробнее

TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer | Hope RugoПодробнее

The best sequence of endocrine treatment in metastatic luminal Breast Cancer:solving the puzzleПодробнее

Breast Cancer | Hope S Rugo, MDПодробнее

“Key Breakthroughs in the Field of Breast Cancer Treatment” by Dr. Hope RugoПодробнее

Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 StudyПодробнее

GS1 03 Discussant Hope S RugoПодробнее